Results 51 to 60 of about 40,867 (262)

Severe Hypocalcemia With Denosumab Among Older Female Dialysis-Dependent Patients.

Journal of the American Medical Association (JAMA)
Importance Dialysis-dependent patients experience high rates of morbidity from fractures, yet little evidence is available on optimal treatment strategies.
Steven T Bird, Elizabeth R. Smith, K. Gelperin, Tae-hyun Jung, Aliza Thompson, Rekha Kambhampati, H. Lyu, Henu Zhao, Yueqin Zhao, Yunfan Zhu, Olivia Easley, Ali Niak, M. Wernecke, Y. Chillarige, Marina Zemskova, Jeffrey A. Kelman, David J. Graham   +16 more
semanticscholar   +1 more source

Risk of Osteonecrosis of the Jaw Under Denosumab Compared to Bisphosphonates in Patients With Osteoporosis

Journal of Bone and Mineral Research, 2021
Osteonecrosis of the jaw (ONJ) is a rare but serious adverse event associated with antiresorptive treatment. There is little evidence regarding the incidence of ONJ among patients with osteoporosis who are treated with denosumab versus bisphosphonates ...
Everts-Graber Judith, L. Daniel, Burkard John-Patrik, S. Benoît, Gahl Brigitta, Häuselmann HansJörg, Studer Ueli, Ziswiler Hans-Rudolf, R. Stephan, Lehmann Thomas   +9 more
semanticscholar   +1 more source

Effects of 24 months of treatment with romosozumab followed by 12 months of denosumab or placebo in postmenopausal women with low bone mineral density : a randomized, double-blind, phase 2, parallel group study [PDF]

, 2018
Over 12 months, romosozumab increased bone formation and decreased bone resorption, resulting in increased bone mineral density (BMD) in postmenopausal women with low BMD (NCT00896532).
Binkley, Bone, Cosman, Cummings, Harrington, Heiss, Langdahl, Leder, Li, Li, McClung, Ominsky, Padhi, Papapoulos, Recknor, Saag, van Bezooijen, Wasnich   +17 more
core   +2 more sources

Denosumab and the Risk of Diabetes in Patients Treated for Osteoporosis

JAMA Network Open
Key Points Question Is denosumab associated with a lower risk of developing diabetes? Findings In this cohort study of 68 510 adults, continued treatment of denosumab for osteoporosis was associated with significantly lower risk of developing diabetes ...
Huei‐Kai Huang, Albert Tzu-Ming Chuang, T. Liao, Shih-Chieh Shao, P. Liu, Yu-Kang Tu, E. C. Lai   +6 more
semanticscholar   +1 more source

Activity of eribulin mesylate in brain metastasis from breast cancer. a stone in a pond? [PDF]

, 2018
Background: Brain metastases develop in approximately 10-25% of patients with metastatic breast cancer (MBC) and are associated with a very poor prognosis.
Catania, G., Cognetti, F., Fabi, A., Gasparro, S., Malaguti, P., Vidiri, A.   +5 more
core   +1 more source

Comparative effectiveness of denosumab vs alendronate among postmenopausal women with osteoporosis

Journal of Bone and Mineral Research
Although clinical trials have shown that denosumab significantly increases bone mineral density at key skeletal sites more than oral bisphosphonates, evidence is lacking from head-to-head randomized trials evaluating fracture outcomes. This retrospective
J. Curtis, T. Arora, Ye Liu, Tzu-Chieh Lin, L. Spangler, Vanessa C Brunetti, R. Stad, M. Mcdermott, B. Bradbury, Min Kim   +9 more
semanticscholar   +1 more source

Treatment With Zoledronate Subsequent to Denosumab in Osteoporosis: A 2‐Year Randomized Study

Journal of Bone and Mineral Research, 2021
Increased bone turnover and rapid bone loss follow discontinuation of denosumab. We investigated the long‐term efficacy of zoledronate (ZOL) in maintaining bone mineral density (BMD) after discontinuation of denosumab.
Anne Sophie Sølling, T. Harsløf, B. Langdahl   +2 more
semanticscholar   +1 more source

Cellular and molecular mediators of bone metastatic lesions [PDF]

, 2018
Bone is the preferential site of metastasis for breast and prostate tumor. Cancer cells establish a tight relationship with the host tissue, secreting factors that stimulate or inhibit bone cells, receiving signals generated from the bone remodeling ...
Battafarano, Giulia, Del Fattore, Andrea, Marampon, Francesco, Rossi, Michela   +3 more
core   +2 more sources

Plain language summary of publication to understand the ROSALIA study: a new biosimilar denosumab for bone health

Therapeutic Advances in Musculoskeletal Disease
Summary What is this summary about? This plain language summary describes the results of a clinical study, ROSALIA , which was published in the Journal of Bone and Mineral Research in 2024. The ROSALIA study looked at whether biosimilar denosumab has the
Richard Eastell, Sławomir Jeka, Maryam Lustberg, Colin Edgerton, Paweł Żuchowski, Barbara Vogg   +5 more
doaj   +1 more source

Systematic review of the clinical effectiveness and cost-effectiveness, and economic evaluation, of denosumab for the treatment of bone metastases from solid tumours

Health Technology Assessment, 2013
Background: Denosumab offers an alternative, or additional, treatment for the prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumours.
J Ford, E Cummins, P Sharma, A Elders, F Stewart, R Johnston, P Royle, R Jones, C Mulatero, R Todd, G Mowatt   +10 more
doaj   +1 more source